
1. indian j med res. 2015 dec;142(6):663-74. doi: 10.4103/0971-5916.174549.

individualization antiretroviral therapy--pharmacogenomic aspect.

dalal b, shankarkumar a(1), ghosh k.

author information: 
(1)department transfusion transmitted disease, national institute of
immunohaematology (icmr), mumbai, india.

combination therapy three drug regimens human immunodeficiency virus
(hiv) infection significantly suppresses viral replication. however, this
therapeutic impact restricted adverse drug events response terms 
short long term efficacy. multiple factors involved different
responses antiretrovirals (arvs) age, body weight, disease status,
diet heredity. pharmacogenomics deals individual genetic make-up its
role drug efficacy toxicity. depth genetic research provided
evidence predict risk developing certain toxicities which
personalized screening surveillance protocols may developed prevent
side effects. describe use pharmacogenomics optimal use of
haart (highly active antiretroviral therapy).

doi: 10.4103/0971-5916.174549 
pmcid: pmc4774063
pmid: 26831415  [indexed medline]

